Hancock, MD, Aug. 19, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announces new name and branding strategy in preparation of beginning the FDA process of its core product Escozine for Pets.
PetLife Pharmaceuticals (Petlife), as part of the preparation for future FDA submission, is rebranding their core product Escozine for PetsTM. Petlife is pleased to announce that VitalzulTM will be the new product name for all PetLife Pharmaceutical products. The Trademark application is underway.
Along with the new name, Petlife Pharmaceuticals is also announcing several new product lines. These product lines include: VitalzulTM Oral, VitalzulTM Enema, VitalzulTM Daily, VitalzulTM Pet Foods and VitalzulTM Treats.
These new products will complement Petlife’s anticipated Pharmacology grade product for Cancer Treatment in pets.
Nutraceutical Grade cancer treatment products are planned in two forms. This formulation of VitalzulTM has been used in clinics around the world.
VitalzulTM Oral: An liquid dose of VitalzulTM Oral makes for easy administration. The solution is colorless and odorless and can be administered through an oral syringe. Pet owners can use this product for their pets in the convenience of their home.
VitalzulTM Enema: This version will be specifically mixed and prepared for immediate enema treatments for dogs and cats. The protocol can be applied by veterinarians or by pet owners. This product will come in one size and additional instructions will indicate amount of solution to use for the size of your pet.
For cancer prevention, Petlife plans to develop additional formulations based on VitalzulTM
VitalzulTM Treat – a natural pet treat preventative
VitalzulTM Daily – a natural daily pet preventative tablet
VitalzulTM Pet Foods – natural preventative foods
It is hoped that these products, when taken consistently, will have the effect of our prolonging pets’ lives and lowering our pets’ risk of cancer as they age. Part of PetLife’s sales and marketing framework is to not only sell the products to companion animals after a cancer diagnosis, but to educate owners about cancer prevention. Petlife’s preventative animal treats, for example, may potentially be an easy way for pet owners to ensure lasting health and viability for their companions.
VitalzulTM is formulated using Petlife’s exclusive worldwide rights to US Patent # US 8097284 B2. “Polarized Dilute Blue Scorpion Venom solution for Veterinary Use”
Petlife Pharmaceuticals will be presenting VitalzulTM at the San Francisco Money Show: August 23-25, 2016.
Petlife’s 506 Private Placement Memorandum is available only to accredited investors.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
CONTACT: Investor Relations: Invicto Group info@invictogroup.com 800-928-7462 Ext. 801
